Clinical and hematologic characteristics of study patients stratified according to the diagnosis of pre-PMF and overt PMF, based on the revised 2016 WHO criteria
| Variables* . | Pre-PMF, N = 278 . | Overt PMF, N = 383 . | P . |
|---|---|---|---|
| Male patients, n (%) | 156 (56.1) | 249 (65.0) | .013 |
| Age | |||
| Median (range), y | 56.6 (18.0-90.3) | 63.6 (14.0-89.8) | <.0001 |
| >65 y, n (%) | 99 (35.6) | 179 (46.7) | .003 |
| Hemoglobin | |||
| Median (range), g/L | 129 (107-175) | 108 (47-150) | <.0001 |
| <100 g/L, n (%) | 37 (13.3) | 136 (35.5) | <.0001 |
| Leukocytes | |||
| Median (range), ×109/L | 9.1 (1.5-150) | 8.2 (1.4-109.0) | .009 |
| >25 × 109/L, n (%) | 18 (6.5) | 31 (8.1) | .252 |
| <4.0 × 109/L, n (%) | 10 (3.6) | 57 (14.9) | <.0001 |
| Platelets | |||
| Median (range), ×109/L | 488 (310-1500) | 249 (19-3279) | <.0001 |
| <100 × 109/L, n (%) | 19 (6.8) | 67 (17.5) | <.0001 |
| Circulating blasts, ≥1%, n (%) | 33 (11.9) | 99 (25.8) | <.0001 |
| LDH, N = 290 | |||
| Median (range), U/L | 388 (127-2806) | 669 (130-2643) | <.0001 |
| >Normal range, n (%) | 98 (81.7) | 159 (93.5) | .011 |
| Constitutional symptoms, n (%) | 57 (20.5) | 129 (33.7) | <.0001 |
| Splenomegaly, n (%) | 177 (63.7) | 317 (82.8) | <.0001 |
| >10 cm from LCM, n (%) | 29 (10.4) | 92 (24.0) | <.0001 |
| Patients with cytogenetic information, N= (% of total) | 150 (54.0) | 182 (47.5) | |
| Abnormal cytogenetics | 27 (18.0) | 69 (37.9) | <.0001 |
| Unfavorable karyotype | 6 (4.0) | 22 (12.1) | .006 |
| IPSS† | |||
| Low | 134 (48.2) | 89 (23.2) | <.0001 |
| Intermediate-1 | 74 (26.6) | 110 (28.7) | |
| Intermediate-2 | 36 (12.9) | 94 (24.6) | |
| High | 34 (12.3) | 90 (23.5) |
| Variables* . | Pre-PMF, N = 278 . | Overt PMF, N = 383 . | P . |
|---|---|---|---|
| Male patients, n (%) | 156 (56.1) | 249 (65.0) | .013 |
| Age | |||
| Median (range), y | 56.6 (18.0-90.3) | 63.6 (14.0-89.8) | <.0001 |
| >65 y, n (%) | 99 (35.6) | 179 (46.7) | .003 |
| Hemoglobin | |||
| Median (range), g/L | 129 (107-175) | 108 (47-150) | <.0001 |
| <100 g/L, n (%) | 37 (13.3) | 136 (35.5) | <.0001 |
| Leukocytes | |||
| Median (range), ×109/L | 9.1 (1.5-150) | 8.2 (1.4-109.0) | .009 |
| >25 × 109/L, n (%) | 18 (6.5) | 31 (8.1) | .252 |
| <4.0 × 109/L, n (%) | 10 (3.6) | 57 (14.9) | <.0001 |
| Platelets | |||
| Median (range), ×109/L | 488 (310-1500) | 249 (19-3279) | <.0001 |
| <100 × 109/L, n (%) | 19 (6.8) | 67 (17.5) | <.0001 |
| Circulating blasts, ≥1%, n (%) | 33 (11.9) | 99 (25.8) | <.0001 |
| LDH, N = 290 | |||
| Median (range), U/L | 388 (127-2806) | 669 (130-2643) | <.0001 |
| >Normal range, n (%) | 98 (81.7) | 159 (93.5) | .011 |
| Constitutional symptoms, n (%) | 57 (20.5) | 129 (33.7) | <.0001 |
| Splenomegaly, n (%) | 177 (63.7) | 317 (82.8) | <.0001 |
| >10 cm from LCM, n (%) | 29 (10.4) | 92 (24.0) | <.0001 |
| Patients with cytogenetic information, N= (% of total) | 150 (54.0) | 182 (47.5) | |
| Abnormal cytogenetics | 27 (18.0) | 69 (37.9) | <.0001 |
| Unfavorable karyotype | 6 (4.0) | 22 (12.1) | .006 |
| IPSS† | |||
| Low | 134 (48.2) | 89 (23.2) | <.0001 |
| Intermediate-1 | 74 (26.6) | 110 (28.7) | |
| Intermediate-2 | 36 (12.9) | 94 (24.6) | |
| High | 34 (12.3) | 90 (23.5) |
LCM, left costal margin.
Where information was available for some patients only, the actual number is indicated (N=). Splenomegaly indicates presence of a palpable spleen below the LCM. Unfavorable karyotype indicates any of the following: +8, −7/7q−, i(17q), inv(3), −5/5q, 12p−, or 11q23 rearrangements.
IPSS uses 5 independent predictors of inferior survival: age, >65 y; hemoglobin, <10 g/dL; leukocytes, >25 × 109/L; circulating blasts ≥1%, constitutional symptoms. The presence of 0, 1, 2, and ≥3 adverse factors defines low-, intermediate-1, intermediate-2, and high-risk disease.